Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 304 entries
Sorted by: Best Match Show Resources per page
Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4).

Diabetology international

Kawasaki R, Kitano S, Sato Y, Yamashita H, Nishimura R, Tajima N.
PMID: 30800559
Diabetol Int. 2018 Apr 26;10(1):3-11. doi: 10.1007/s13340-018-0357-z. eCollection 2019 Jan.

AIMS: This study aims to identify associations of non-proliferative diabetic retinopathy (NPDR) in the Japan Diabetes Complication and its Prevention prospective (JDCP) study, a nation-wide study capturing real-world practice for diabetes in Japan.METHODS: We recruited patients with type 1...

Cite
Kawasaki R, Kitano S, Sato Y, et al. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetol Int. 2018;10(1):3-11doi: 10.1007/s13340-018-0357-z.
Kawasaki, R., Kitano, S., Sato, Y., Yamashita, H., Nishimura, R., Tajima, N. (2019). Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetology international, 10(1), 3-11. https://doi.org/10.1007/s13340-018-0357-z
Kawasaki, Ryo, et al. "Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4)." Diabetology international vol. 10,1 (2019): 3-11. doi: https://doi.org/10.1007/s13340-018-0357-z
Kawasaki R, Kitano S, Sato Y, Yamashita H, Nishimura R, Tajima N. Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). Diabetol Int. 2018 Apr 26;10(1):3-11. doi: 10.1007/s13340-018-0357-z. eCollection 2019 Jan. PMID: 30800559; PMCID: PMC6357241.
Copy Download .nbib Format: NLM
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.

Diabetology international

Ishihara H, Yamaguchi S, Nakao I, Asahina S, Sakatani T.
PMID: 30800562
Diabetol Int. 2018 Jul 16;10(1):37-50. doi: 10.1007/s13340-018-0359-x. eCollection 2019 Jan.

OBJECTIVE: To examine long-term efficacy/safety of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, added to ongoing insulin therapy in Japanese patients with type 2 diabetes.METHODS: We conducted a 36-week, open-label extension of ipragliflozin therapy following a 16-week, randomized, placebo-controlled, double-blind...

Cite
Ishihara H, Yamaguchi S, Nakao I, et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. Diabetol Int. 2018;10(1):37-50doi: 10.1007/s13340-018-0359-x.
Ishihara, H., Yamaguchi, S., Nakao, I., Asahina, S., & Sakatani, T. (2019). Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. Diabetology international, 10(1), 37-50. https://doi.org/10.1007/s13340-018-0359-x
Ishihara, Hisamitsu, et al. "Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study." Diabetology international vol. 10,1 (2019): 37-50. doi: https://doi.org/10.1007/s13340-018-0359-x
Ishihara H, Yamaguchi S, Nakao I, Asahina S, Sakatani T. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. Diabetol Int. 2018 Jul 16;10(1):37-50. doi: 10.1007/s13340-018-0359-x. eCollection 2019 Jan. PMID: 30800562; PMCID: PMC6357239.
Copy Download .nbib Format: NLM
Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes.

Diabetology international

Chang CH, Sakaguchi M.
PMID: 31938683
Diabetol Int. 2019 Aug 14;11(1):57-66. doi: 10.1007/s13340-019-00405-w. eCollection 2020 Jan.

OBJECTIVES: To identify the association of type 2 diabetes (T2DM) and liver disease with elevated ALT and factors associated with increased ALT in patients with and without T2DM.DESIGN AND SETTING: We performed a retrospective study in adults with ≥...

Cite
Chang CH, Sakaguchi M. Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes. Diabetol Int. 2019;11(1):57-66doi: 10.1007/s13340-019-00405-w.
Chang, C. H., & Sakaguchi, M. (2020). Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes. Diabetology international, 11(1), 57-66. https://doi.org/10.1007/s13340-019-00405-w
Chang, Chia-Hsien, and Sakaguchi, Motonobu. "Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes." Diabetology international vol. 11,1 (2020): 57-66. doi: https://doi.org/10.1007/s13340-019-00405-w
Chang CH, Sakaguchi M. Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes. Diabetol Int. 2019 Aug 14;11(1):57-66. doi: 10.1007/s13340-019-00405-w. eCollection 2020 Jan. PMID: 31938683; PMCID: PMC6942058.
Copy Download .nbib Format: NLM
Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus: a cross-sectional study.

Diabetology international

Tanaka M, Yamamoto T, Kuribayashi N, Okuguchi F, Isotani H, Iwamoto M, Sugimoto H, Nakagawa O, Suzuki D, Abe K, Watanabe N, Minabe M, Fuchida S, Yokoyama H.
PMID: 32206482
Diabetol Int. 2019 Oct 16;11(2):121-128. doi: 10.1007/s13340-019-00413-w. eCollection 2020 Apr.

BACKGROUND: Our previous pilot study using patients with type 2 diabetes mellitus in one medical clinic showed an association of urinary albumin excretion, a marker of generalized vascular dysfunction and kidney damage, with periodontitis. The purpose of this study...

Cite
Tanaka M, Yamamoto T, Kuribayashi N, et al. Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus: a cross-sectional study. Diabetol Int. 2019;11(2):121-128doi: 10.1007/s13340-019-00413-w.
Tanaka, M., Yamamoto, T., Kuribayashi, N., Okuguchi, F., Isotani, H., Iwamoto, M., Sugimoto, H., Nakagawa, O., Suzuki, D., Abe, K., Watanabe, N., Minabe, M., Fuchida, S., & Yokoyama, H. (2020). Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus: a cross-sectional study. Diabetology international, 11(2), 121-128. https://doi.org/10.1007/s13340-019-00413-w
Tanaka, Michio, et al. "Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus: a cross-sectional study." Diabetology international vol. 11,2 (2020): 121-128. doi: https://doi.org/10.1007/s13340-019-00413-w
Tanaka M, Yamamoto T, Kuribayashi N, Okuguchi F, Isotani H, Iwamoto M, Sugimoto H, Nakagawa O, Suzuki D, Abe K, Watanabe N, Minabe M, Fuchida S, Yokoyama H. Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus: a cross-sectional study. Diabetol Int. 2019 Oct 16;11(2):121-128. doi: 10.1007/s13340-019-00413-w. eCollection 2020 Apr. PMID: 32206482; PMCID: PMC7082441.
Copy Download .nbib Format: NLM
Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.

Diabetology international

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.
PMID: 32206488
Diabetol Int. 2019 Dec 20;11(2):163. doi: 10.1007/s13340-019-00422-9. eCollection 2020 Apr.

[This corrects the article DOI: 10.1007/s13340-018-0345-3.].

Cite
Haneda M, Noda M, Origasa H, et al. Correction to: Japanese Clinical Practice Guideline for Diabetes 2016. Diabetol Int. 2019;11(2):163doi: 10.1007/s13340-019-00422-9.
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2020). Correction to: Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology international, 11(2), 163. https://doi.org/10.1007/s13340-019-00422-9
Haneda, Masakazu, et al. "Correction to: Japanese Clinical Practice Guideline for Diabetes 2016." Diabetology international vol. 11,2 (2020): 163. doi: https://doi.org/10.1007/s13340-019-00422-9
Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Correction to: Japanese Clinical Practice Guideline for Diabetes 2016. Diabetol Int. 2019 Dec 20;11(2):163. doi: 10.1007/s13340-019-00422-9. eCollection 2020 Apr. PMID: 32206488; PMCID: PMC7082432.
Copy Download .nbib Format: NLM
Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level.

Diabetology international

Bando Y, Wakaguri H, Aoki K, Kanehara H, Hisada A, Okafuji K, Toya D, Tanaka N.
PMID: 30603241
Diabetol Int. 2015 Feb 27;7(1):34-41. doi: 10.1007/s13340-015-0208-0. eCollection 2016 Mar.

AIM: To determine whether non-high-density lipoprotein cholesterol (non-HDL-C) level, in comparison with low-density lipoprotein cholesterol (LDL-C) level, is useful for predicting the values of various surrogate atherosclerosis markers in Japanese subjects with type 2 diabetes (T2DM).METHODS: Data were retrieved...

Cite
Bando Y, Wakaguri H, Aoki K, et al. Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level. Diabetol Int. 2015;7(1):34-41doi: 10.1007/s13340-015-0208-0.
Bando, Y., Wakaguri, H., Aoki, K., Kanehara, H., Hisada, A., Okafuji, K., Toya, D., & Tanaka, N. (2016). Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level. Diabetology international, 7(1), 34-41. https://doi.org/10.1007/s13340-015-0208-0
Bando, Yukihiro, et al. "Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level." Diabetology international vol. 7,1 (2016): 34-41. doi: https://doi.org/10.1007/s13340-015-0208-0
Bando Y, Wakaguri H, Aoki K, Kanehara H, Hisada A, Okafuji K, Toya D, Tanaka N. Non-high-density cholesterol level as a predictor of maximum carotid intima-media thickness in Japanese subjects with type 2 diabetes: a comparison with low-density lipoprotein level. Diabetol Int. 2015 Feb 27;7(1):34-41. doi: 10.1007/s13340-015-0208-0. eCollection 2016 Mar. PMID: 30603241; PMCID: PMC6214466.
Copy Download .nbib Format: NLM
Deletion of SIRT1 in myeloid cells impairs glucose metabolism with enhancing inflammatory response to adipose tissue hypoxia.

Diabetology international

Takikawa A, Usui I, Fujisaka S, Ikutani M, Senda S, Hattori S, Tsuneyama K, Koshimizu Y, Inoue R, Tanaka-Hayashi A, Nakagawa T, Nagai Y, Takatsu K, Sasaoka T, Mori H, Tobe K.
PMID: 30603244
Diabetol Int. 2015 May 29;7(1):59-68. doi: 10.1007/s13340-015-0213-3. eCollection 2016 Mar.

Chronic inflammation is a pathophysiology of insulin resistance in metabolic diseases, such as obesity and type 2 diabetes. Adipose tissue macrophages (ATMs) play important roles in this inflammatory process. SIRT1 is implicated in the regulation of glucose metabolism in...

Cite
Takikawa A, Usui I, Fujisaka S, et al. Deletion of SIRT1 in myeloid cells impairs glucose metabolism with enhancing inflammatory response to adipose tissue hypoxia. Diabetol Int. 2015;7(1):59-68doi: 10.1007/s13340-015-0213-3.
Takikawa, A., Usui, I., Fujisaka, S., Ikutani, M., Senda, S., Hattori, S., Tsuneyama, K., Koshimizu, Y., Inoue, R., Tanaka-Hayashi, A., Nakagawa, T., Nagai, Y., Takatsu, K., Sasaoka, T., Mori, H., & Tobe, K. (2016). Deletion of SIRT1 in myeloid cells impairs glucose metabolism with enhancing inflammatory response to adipose tissue hypoxia. Diabetology international, 7(1), 59-68. https://doi.org/10.1007/s13340-015-0213-3
Takikawa, Akiko, et al. "Deletion of SIRT1 in myeloid cells impairs glucose metabolism with enhancing inflammatory response to adipose tissue hypoxia." Diabetology international vol. 7,1 (2016): 59-68. doi: https://doi.org/10.1007/s13340-015-0213-3
Takikawa A, Usui I, Fujisaka S, Ikutani M, Senda S, Hattori S, Tsuneyama K, Koshimizu Y, Inoue R, Tanaka-Hayashi A, Nakagawa T, Nagai Y, Takatsu K, Sasaoka T, Mori H, Tobe K. Deletion of SIRT1 in myeloid cells impairs glucose metabolism with enhancing inflammatory response to adipose tissue hypoxia. Diabetol Int. 2015 May 29;7(1):59-68. doi: 10.1007/s13340-015-0213-3. eCollection 2016 Mar. PMID: 30603244; PMCID: PMC6224900.
Copy Download .nbib Format: NLM
Combination of type 2 diabetes and smoking increases total cancer mortality in Japanese men using competing risk analysis: the Tanno-Sobetsu study.

Diabetology international

Ohnishi H, Saitoh S, Akasaka H, Furukawa T, Mori M, Miura T.
PMID: 30603260
Diabetol Int. 2015 Aug 25;7(2):167-172. doi: 10.1007/s13340-015-0232-0. eCollection 2016 Jun.

AIMS: We assessed the impact of the combination of type 2 diabetes (T2DM) and smoking on total cancer mortality using cohort data of a general Japanese population.METHODS: Of 1908 residents who received health checkups in two towns in 1994,...

Cite
Ohnishi H, Saitoh S, Akasaka H, et al. Combination of type 2 diabetes and smoking increases total cancer mortality in Japanese men using competing risk analysis: the Tanno-Sobetsu study. Diabetol Int. 2015;7(2):167-172doi: 10.1007/s13340-015-0232-0.
Ohnishi, H., Saitoh, S., Akasaka, H., Furukawa, T., Mori, M., & Miura, T. (2016). Combination of type 2 diabetes and smoking increases total cancer mortality in Japanese men using competing risk analysis: the Tanno-Sobetsu study. Diabetology international, 7(2), 167-172. https://doi.org/10.1007/s13340-015-0232-0
Ohnishi, Hirofumi, et al. "Combination of type 2 diabetes and smoking increases total cancer mortality in Japanese men using competing risk analysis: the Tanno-Sobetsu study." Diabetology international vol. 7,2 (2016): 167-172. doi: https://doi.org/10.1007/s13340-015-0232-0
Ohnishi H, Saitoh S, Akasaka H, Furukawa T, Mori M, Miura T. Combination of type 2 diabetes and smoking increases total cancer mortality in Japanese men using competing risk analysis: the Tanno-Sobetsu study. Diabetol Int. 2015 Aug 25;7(2):167-172. doi: 10.1007/s13340-015-0232-0. eCollection 2016 Jun. PMID: 30603260; PMCID: PMC6224999.
Copy Download .nbib Format: NLM
Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan.

Diabetology international

Ikeda Y, Tsukube S, Kadowaki T, Odawara M.
PMID: 30603263
Diabetol Int. 2015 Oct 05;7(2):188-198. doi: 10.1007/s13340-015-0236-9. eCollection 2016 Jun.

OBJECTIVES: We aimed to identify diabetes-related factors associated with achieving HbA1c

Cite
Ikeda Y, Tsukube S, Kadowaki T, et al. Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. Diabetol Int. 2015;7(2):188-198doi: 10.1007/s13340-015-0236-9.
Ikeda, Y., Tsukube, S., Kadowaki, T., & Odawara, M. (2016). Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. Diabetology international, 7(2), 188-198. https://doi.org/10.1007/s13340-015-0236-9
Ikeda, Yukio, et al. "Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan." Diabetology international vol. 7,2 (2016): 188-198. doi: https://doi.org/10.1007/s13340-015-0236-9
Ikeda Y, Tsukube S, Kadowaki T, Odawara M. Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. Diabetol Int. 2015 Oct 05;7(2):188-198. doi: 10.1007/s13340-015-0236-9. eCollection 2016 Jun. PMID: 30603263; PMCID: PMC6225007.
Copy Download .nbib Format: NLM
Roles of the interorgan neuronal network in the development of metabolic syndrome.

Diabetology international

Uno K.
PMID: 30603265
Diabetol Int. 2016 Jul 05;7(3):205-211. doi: 10.1007/s13340-016-0277-8. eCollection 2016 Sep.

Metabolic processes in different tissues and remote organs are under coordinated systemic regulation, allowing adaptation to a variety of external circumstances. Neuronal signals as well as humoral factors, such as nutrients, growth factors, and hormones, have attracted increasing attention...

Cite
Uno K. Roles of the interorgan neuronal network in the development of metabolic syndrome. Diabetol Int. 2016;7(3):205-211doi: 10.1007/s13340-016-0277-8.
Uno, K. (2016). Roles of the interorgan neuronal network in the development of metabolic syndrome. Diabetology international, 7(3), 205-211. https://doi.org/10.1007/s13340-016-0277-8
Uno, Kenji. "Roles of the interorgan neuronal network in the development of metabolic syndrome." Diabetology international vol. 7,3 (2016): 205-211. doi: https://doi.org/10.1007/s13340-016-0277-8
Uno K. Roles of the interorgan neuronal network in the development of metabolic syndrome. Diabetol Int. 2016 Jul 05;7(3):205-211. doi: 10.1007/s13340-016-0277-8. eCollection 2016 Sep. PMID: 30603265; PMCID: PMC6224984.
Copy Download .nbib Format: NLM
Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.

Diabetology international

Kashiwagi A, Yoshida S, Kawamuki K, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Akiyama N, Kondo Y, Ogihara T.
PMID: 30603310
Diabetol Int. 2016 Sep 09;8(1):76-86. doi: 10.1007/s13340-016-0283-x. eCollection 2017 Mar.

Our aim was to examine the effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus (T2DM). We conducted a pooled analysis of double-blind trials of Japanese T2DM patients,...

Cite
Kashiwagi A, Yoshida S, Kawamuki K, et al. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetol Int. 2016;8(1):76-86doi: 10.1007/s13340-016-0283-x.
Kashiwagi, A., Yoshida, S., Kawamuki, K., Nakamura, I., Kazuta, K., Ueyama, E., Takahashi, H., Akiyama, N., Kondo, Y., & Ogihara, T. (2017). Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetology international, 8(1), 76-86. https://doi.org/10.1007/s13340-016-0283-x
Kashiwagi, Atsunori, et al. "Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials." Diabetology international vol. 8,1 (2017): 76-86. doi: https://doi.org/10.1007/s13340-016-0283-x
Kashiwagi A, Yoshida S, Kawamuki K, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Akiyama N, Kondo Y, Ogihara T. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetol Int. 2016 Sep 09;8(1):76-86. doi: 10.1007/s13340-016-0283-x. eCollection 2017 Mar. PMID: 30603310; PMCID: PMC6224932.
Copy Download .nbib Format: NLM
Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes.

Diabetology international

Kawamori D.
PMID: 30603330
Diabetol Int. 2017 Jun 29;8(3):248-256. doi: 10.1007/s13340-017-0327-x. eCollection 2017 Aug.

Pancreatic islet dysfunction, including impaired insulin secretion in β cells and dysregulated glucagon secretion in α cells, is the chief pathology of diabetes. In β cells, oxidative stress, evoked by chronic hyperglycemia, was found to induce dysfunction of a...

Cite
Kawamori D. Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes. Diabetol Int. 2017;8(3):248-256doi: 10.1007/s13340-017-0327-x.
Kawamori, D. (2017). Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes. Diabetology international, 8(3), 248-256. https://doi.org/10.1007/s13340-017-0327-x
Kawamori, Dan. "Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes." Diabetology international vol. 8,3 (2017): 248-256. doi: https://doi.org/10.1007/s13340-017-0327-x
Kawamori D. Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes. Diabetol Int. 2017 Jun 29;8(3):248-256. doi: 10.1007/s13340-017-0327-x. eCollection 2017 Aug. PMID: 30603330; PMCID: PMC6224887.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 304 entries